Drug Trial Radar · NCT01348152
Effect of TU-100 in Patients With Functional Constipation
Last checked: Nov 19, 2026Latest source record: Sep 17, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
50
Actual
Start
Sep 2011
Primary completion
Jul 2013
Study completion Jul 2013
Sponsor
- Lead sponsor
- Tsumura USAIndustry
- Sponsor type
- Industry
- Collaborators
- Cato Research
- First posted
- May 5, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the improvement in the severity of constipation (from Baseline to Day 28), determined by the constipation severity instrument (CSI) score \[1\], compared to placebo, following a total daily oral dose of 15 g TU-100 administered for 28 consecutive days in adult subjects with functional constipation.
Conditions
- Functional Constipation
Interventions
DAIKENCHUTO (TU-100)Drug
Subjects will be randomized to 15 g/day of TU-100. Dosage is granule. Subjects will ingest two 2.5 g doses of TU-100 three times daily for 34 consecutive days.
PlaceboDrug
Subjects will be randomized to 15 g/day of placebo. Dosage is granule. Subjects will ingest two 2.5 g doses of placebo three times daily for 34 consecutive days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline to Day 28 in CSI total scoreTime frame: Up to 10 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Colon and Rectal Surgery Associates
Minneapolis, Minnesota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.